TGA approves new diagnostic agent

31 August 2016 - The TGA has approved Juno Pharmaceuticals' Hexvix.

The TGA approved hexaminolevulinate hydrochloride on 16 August 2016 for use as an adjunct to standard white light cystoscopy to contribute to the diagnosis and management of bladder cancer in patients with known or high suspicion of bladder cancer.

Read TGA announcement

Michael Wonder

Posted by:

Michael Wonder